BriaCell Therapeutics Corp Warrants(24/04/2030) BCTXZ 深 沪
等待开盘 07-18 09:30:00 美东时间
0.33
+0.030
+10.04%
华盛通- 最 高0.36
- 今 开0.36
- 成交量 15.80万股
- 最 低 0.25
- 昨 收 0.2999
- 总市值 0
- 52周最高 1.515
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.1769
- 委 比 82.56%
- 总股本 --
- 历史最高 1.515
- 量 比 2.13
- 振 幅 36.68%
- 历史最低 0.1769
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
07-16 20:05
BriaCell Therapeutics Reports Updated Results From Ongoing Phase 2 Study Of Bria-IMT In Combination With Check Point Inhibitor In Patients With Advanced Metastatic Breast Cancer
Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment"Eye bulging" metastatic breast cancer patient had failed 8 prior regimens, including
07-10 19:34
BriaCell Adds Two Key Large Cancer Centers To Ongoing Pivotal Phase 3 Clinical Study; Expects Completing Patient Enrollment In Late 2025 Or Early 2026 And May Report Top Line Data As Early As H1-2026
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 studyBriaCell's Phase 3 study currently has 58 active clinical
07-02 19:37
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
BriaCell Therapeutics has expanded its pivotal Phase 3 clinical study by adding 30 satellite locations through Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven. The study now includes 58 active sites across 15 states. BriaCell aims to complete patient enrollment by late 2025 or early 2026, with potential top-line data available as early as H1-2026. The Phase 3 trial evaluates Bria-IMT plus immune checkpoint inhibitor in adv...
07-02 11:30
BriaCell Highlights Breast Cancer Trial Data at 2025 ASCO Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical
06-02 19:34
BriaCell Therapeutics To Highlight Survival And Clinical Benefit Data In Three Clinical Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuationsSuccessful completion of the pivotal
05-23 19:33
